NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Oncolytics Biotech, Inc. (NASDAQ: ONCY)
ONCY Technical Analysis
5
As on 4th Nov 2015 ONCY Share Price closed @ 0.33 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.60 & Strong Sell for SHORT-TERM with Stoploss of 0.49 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ONCY Share Price
Open | 0.36 | Change | Price | % |
High | 0.36 | 1 Day | -0.02 | -5.71 |
Low | 0.31 | 1 Week | 0.00 | 0.00 |
Close | 0.33 | 1 Month | 0.00 | 0.00 |
Volume | 802355 | 1 Year | 0.00 | 0.00 |
52 Week High 5.79 | 52 Week Low 2.98 |
NASDAQ USA Most Active Stocks
YHOO | 52.58 | 0.00% |
FNFG | 10.18 | -0.20% |
DELL | 13.86 | 0.22% |
RFMD | 16.59 | -2.07% |
MU | 44.31 | 6.39% |
RIMM | 13.03 | 0.39% |
BBEP | 0.12 | 0.00% |
GTAT | 0.44 | 0.00% |
SUSQ | 14.20 | -0.77% |
INTC | 45.49 | 2.52% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
ONCY Daily Charts |
ONCY Intraday Charts |
Whats New @ Bazaartrend |
ONCY Free Analysis |
|
ONCY Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
RESISTANCE | 0.38 |
RESISTANCE | 0.36 |
SUPPORT | 0.30 |
SUPPORT | 0.28 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
ONCY Target for Month January
4th UP TARGET | 0 |
3rd UP TARGET | 0 |
2nd UP TARGET | 0 |
1st UP TARGET | 0 |
1st DOWN TARGET | 0 |
2nd DOWN TARGET | 0 |
3rd DOWN TARGET | 0 |
4th DOWN TARGET | 0 |
ONCY Weekly Target
4th UP TARGET | 0.00 |
3rd UP TARGET | 0.00 |
2nd UP TARGET | 0.00 |
1st UP TARGET | 0.00 |
1st DOWN TARGET | 0.00 |
2nd DOWN TARGET | 0.00 |
3rd DOWN TARGET | 0.00 |
4th DOWN TARGET | 0.00 |
ONCY Target for Year 2021
4th UP TARGET | 0 |
3rd UP TARGET | 0 |
2nd UP TARGET | 0 |
1st UP TARGET | 0 |
1st DOWN TARGET | 0 |
2nd DOWN TARGET | 0 |
3rd DOWN TARGET | 0 |
4th DOWN TARGET | 0 |
Oncolytics Biotech, Inc. ( NASDAQ USA Symbol : ONCY )
Sector : N/AIndustry:N/AFull Time Employees:N/ABusiness Summary Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOL And Other Stocks in Same Sector
Sector : N/AIndustry:N/AFull Time Employees:N/ABusiness Summary Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOL And Other Stocks in Same Sector
ONCY Other Details
Segment | EQ | |
Market Capital | 153322176.00 | |
Sector | N/AIndustry:N/AFull Time Employees:N/ABusiness Summary Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOL | |
Industry | N/AFull Time Employees:N/ABusiness Summary Oncolytics Biotech Inc., a development stage biophar | |
Offical website | > echo $website ; ?> |
ONCY Address
![]() |
1167 Kensington Crescent NW Suite 210 Calgary, AB T2N 1X7 Canada Phone: 403-670-7377 Fax: 403-283-0858 |
ONCY Latest News
ONCY Business Profile
Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program. Oncolytics uses contract toll manufacturers to produce REOLYSIN.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service